Related Experiment Videos
Jiwei Zhang1, Fen Ma1, Zhe Li2
1Shanghai Key Laboratory of Compound Chinese Medicines The MOE Key Laboratory for Standardization of Chinese Medicines Institute of Chinese Materia Medica Shanghai University of Traditional Chinese Medicine Shanghai China.
Abstract:
This study systematically analyzed the molecular mechanism and function of nuclear factor kappa B subunit 2 (NFKB2) in colorectal cancer (CRC) to investigate the potential of NFKB2 as a therapeutic target for CRC. Various experimental techniques, including RNA sequencing, proteome chip assays, and small molecule analysis, were used to obtain a deeper understanding of the regulation of NFKB2 in CRC. The results revealed that NFKB2 was upregulated in a significant proportion of patients with advanced hepatic metastasis of CRC. NFKB2 played an important role in promoting tumor growth through CD8+ T-cell exhaustion. Moreover, NFKB2 directly interacted with signal transducer and activator of transcription 2 (STAT2), leading to increased phosphorylation of STAT2 and the upregulation of programmed death ligand 1 (PD-L1). Applying a small molecule inhibitor of NFKB2 (Rg5) led to a reduction in PD-L1 expression and improved response to programmed death-1 blockade-based immunotherapy. In conclusion, the facilitated NFKB2-STAT2/PD-L1 axis may suppress immune surveillance in CRC and targeting NFKB2 may enhance the efficacy of immunotherapeutic strategies. Our results provide novel insights into the molecular mechanisms underlying the contribution of NFKB2 in CRC immune escape.
Insights
Nuclear factor kappa B subunit 2 (NFKB2) promotes colorectal cancer (CRC) growth and immune escape by upregulating PD-L1. Targeting NFKB2 may enhance immunotherapy effectiveness for CRC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Context:
- Colorectal cancer (CRC) exhibits complex immune evasion mechanisms.
- Nuclear factor kappa B subunit 2 (NFKB2) is implicated in cancer progression.
Purpose:
- To elucidate the molecular mechanism and function of NFKB2 in CRC.
- To evaluate NFKB2 as a potential therapeutic target for CRC.
Summary:
- NFKB2 is upregulated in advanced CRC with hepatic metastasis, promoting tumor growth via CD8+ T-cell exhaustion.
- NFKB2 interacts with STAT2, increasing STAT2 phosphorylation and PD-L1 expression.
- Inhibition of NFKB2 with Rg5 reduced PD-L1 and improved response to PD-1 blockade immunotherapy.
Impact:
- Identifies the NFKB2-STAT2/PD-L1 axis as a key regulator of CRC immune suppression.
- Suggests targeting NFKB2 can enhance CRC immunotherapy efficacy.
- Provides novel insights into CRC immune escape mechanisms.